Children with Asthma Receiving Dupilumab had Reduced Exacerbations and Improved Asthma Control Versus Placebo, Regardless of Asthma Duration

Klinische Pädiatrie 2026

View at publisher
Authors: Wanda Phipatanakul, T W Guilbert, Monika Gappa, K Ross, Jérôme Msihid, Rebecca Gall, Olivier Ledanois, Eckard H. Hamelmann
DOI: 10.1055/s-0046-1816707
Cited by: 0

Abstract

Rationale: Post hoc analysis of phase 3 VOYAGE (NCT02948959) investigated dupilumab efficacy by asthma duration (since first asthma diagnosis:≤4,>4–− 1.64), and clinical remission. Results: Three-hundred-fifty children received dupilumab 100/200 mg or placebo q2w for 52 weeks. Dupilumab vs placebo reduced annualized exacerbation rates across all subgroups (asthma duration≤4 years: 68%,>4–4–4–4–4–

Fields of Study & Subjects

Asthma and respiratory diseases Dermatology and Skin Diseases Allergic Rhinitis and Sensitization

Publication details

Journal / source
Klinische Pädiatrie
Volume
238
Publication date
1 February 2026
Language
EN